Parabilis Therapeutics (PBLS Proposed) upsized its IPO to 33.33 million shares – up from 25 million initially – and keeping the price range at $17.00 to $19.00 – to raise $600 million, if priced at the $18.00 mid-point of its range, according to an S-1/A filing early today – Tuesday, June 9, 2026. The cancer biotech’s IPO is set to price tonight – after the closing bell – to trade tomorrow – Wednesday, June 10, 2026 – on the NASDAQ. The books closed yesterday afternoon at 4 P.M. EDT.
Leerink Partners and BofA Securities are leading the joint book-runners’ team, which includes Evercore ISI, Guggenheim Partners and LifeSci Capital.
Parabilis Therapeutics, based in Cambridge, Massachusetts, plans to start a Phase 3 registrational trial of its leading drug candidate, zolucatetide, to treat patients with desmoid tumors in the first half of 2027, the prospectus said.
The biotech entered into a license and collaboration agreement with Regeneron Pharmaceuticals in May, according to the prospectus. Regeneron has agreed to buy $75 million of Parabilis Therapeutics’ stock at 90 percent of the IPO price in a private placement to be conducted in conjunction with the IPO, the prospectus said.
Principal shareholders include RA Capital, the ARCH Venture Fund and Google Ventures, the prospectus said.
Parabilis Therapeutics is not profitable: The company reported a net loss of $152.88 million on no revenue for the 12 months that ended March 31, 2026, according to financial statements in the prospectus.
(For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.